Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00674986 · ClinicalTrials.gov registry record · NA
A Clinical Study to Evaluate the Use of Episodic, Intensive Blood Glucose Monitoring in Persons With Non-insulin Treated Type 2 Diabetes
A NA study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- NA
- Development phase
- 522
- Enrollment target
NCT00674986: Completed NA study, sponsored by Hoffmann-La Roche.
NCT00674986 is a NA study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 522 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (63% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00674986, a NA study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- NA
- Development phase
- 522 participants
- Enrollment target
Study Summary
This randomized, parallel group study will determine whether the use of episodic, intensive glucose monitoring via the Accu-Chek 360 view blood glucose analysis system has a positive effect on overall glycemic control. Patients will be randomized into either the 'usual care' group, or the 'interventional group' supplemented with the Accu-Chek 360 view blood glucose analysis system. The effect of each treatment regimen on glycemic control will be assessed by measurement of change in baseline HbA1c values at 12 months. The anticipated time on study treatment is 1 year, and the target sample size is 504 individuals.
Primary Outcome
Blood was collected at Baseline and Month 12 and analyzed at a central laboratory for HbA1c. Results were calculated using a Linear Mixed Model with study group, visit, group-by-visit interaction, baseline HbA1c, gender, age, and race as fixed effects; and site and subject as random effects. A negative change from Baseline indicated improvement.
Interventions
- DEVICE Accu-Chek 360° View Blood Glucose Analysis Tool
- DEVICE Accu-Chek Aviva Glucose Meter
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 522 participants |
| Start Date | 2008-03 |
| Est. Completion | 2010-02 |
| Phase | NA |
What the finished NCT00674986 record still lists
NCT00674986 is an interventional study that assigns participants to a tested intervention. The registered 522 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (63% lower).
The record links to 0 conditions, and to 2 interventions - of which Accu-Chek 360° View Blood Glucose Analysis Tool is the first listed.
NCT00674986 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00674986 about?
NCT00674986 is a clinical study titled "A Clinical Study to Evaluate the Use of Episodic, Intensive Blood Glucose Monitoring in Persons With Non-insulin Treated Type 2 Diabetes". This randomized, parallel group study will determine whether the use of episodic, intensive glucose monitoring via the Accu-Chek 360 view blood glucose analysis system has a positive effect on overall glycemic control. Patients will be randomized into either the 'usual care' group, or the 'intervent...
What is the current status of trial NCT00674986?
This trial is currently completed. It is a NA study. The enrollment target is 522 participants. The study started on 2008-03. Estimated completion is 2010-02.
What interventions are being tested in trial NCT00674986?
The interventions under investigation include: Accu-Chek 360° View Blood Glucose Analysis Tool (DEVICE), Accu-Chek Aviva Glucose Meter (DEVICE).
Who is sponsoring clinical trial NCT00674986?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00674986's enrollment target sits among peer trials
522 189th of 2000 higher than 1,811 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06835686 · 522 participants · NA
Collaborative Multi-level Obesity Intervention Engaging Underserved Communities Trial
- NCT06894212 · 522 participants · Phase 3
A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia
- NCT03526835 · 523 participants · Phase 1
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
- NCT04580134 · 524 participants · Phase 4
CLOZAPINE Response in Biotype-1
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia